Literature DB >> 16842545

Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats.

Min Pan1, Yu-Lin Song, Jian-Ming Xu, Hui-Zhong Gan.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized condition that may progress to end-stage liver disease, which ranges from simple steatosis to steatohepatitis, advanced fibrosis, and cirrhosis. Oxidative stress and lipid peroxidation are key pathophysiological mechanisms in NAFLD. We investigate the preventive effects of intraperitoneal administration of melatonin (2.5, 5, 10 mg/kg, daily, respectively) in NAFLD rats induced by high-fat diets for 12 wk. Liver damage was evaluated by serological analysis, serum and hepatic lipid assay as well as hematoxylin-eosin staining in liver sections. Oxidative stress and lipid peroxidation were assessed by measuring malondialdehyde (MDA) levels and superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities in liver. The results showed that high-fat diet induced oxidative stress with extensive liver steatosis in rats. Melatonin (5 or 10 mg/kg) was effective in reducing hepatic steatosis and inflammation with lowering serum alanine aminotransferase, aspartate aminotransferase, and levels liver total cholesterol and triglycerides in high-fat diet rats. Moreover, melatonin (2.5, 5, 10 mg/kg) increased SOD and GSH-Px activities and the 10 mg/kg dose of melatonin reduced MDA levels in liver. This study shows that melatonin exerts protective effects against fatty liver in rats induced by high-fat diet possibly through its antioxidant actions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842545     DOI: 10.1111/j.1600-079X.2006.00346.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  40 in total

1.  Role of melatonin on diabetes-related metabolic disorders.

Authors:  Javier Espino; José A Pariente; Ana B Rodríguez
Journal:  World J Diabetes       Date:  2011-06-15

Review 2.  Melatonin, mitochondria, and the metabolic syndrome.

Authors:  Daniel P Cardinali; Daniel E Vigo
Journal:  Cell Mol Life Sci       Date:  2017-08-17       Impact factor: 9.261

3.  Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.

Authors:  Sawsan A Zaitone; Bassant M Barakat; Shymaa E Bilasy; Manal S Fawzy; Eman Z Abdelaziz; Noha E Farag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-24       Impact factor: 3.000

Review 4.  Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Shao-Ren Zhang; Xiao-Ming Fan
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

5.  Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development.

Authors:  Yan Li; Jie Hai; Lake Li; Xuehui Chen; Hua Peng; Meng Cao; Qinggui Zhang
Journal:  Endocrine       Date:  2012-07-29       Impact factor: 3.633

6.  Vitamin D and melatonin protect the cell's viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines.

Authors:  Dilşad Özerkan; Nesrin Özsoy; Erkan Yılmaz
Journal:  Cytotechnology       Date:  2014-07-06       Impact factor: 2.058

7.  Melatonin attenuates high fat diet-induced fatty liver disease in rats.

Authors:  Gregorios Hatzis; Panayiotis Ziakas; Nikolaos Kavantzas; Aggeliki Triantafyllou; Panagiotis Sigalas; Ioanna Andreadou; Konstantinos Ioannidis; Stamatios Chatzis; Konstantinos Filis; Alexandros Papalampros; Fragiska Sigala
Journal:  World J Hepatol       Date:  2013-04-27

Review 8.  Melatonin role preventing steatohepatitis and improving liver transplantation results.

Authors:  Eduardo Esteban-Zubero; Francisco Agustín García-Gil; Laura López-Pingarrón; Moisés Alejandro Alatorre-Jiménez; José Manuel Ramírez; Dun-Xian Tan; José Joaquín García; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

Review 9.  Possible application of melatonin treatment in human diseases of the biliary tract.

Authors:  Leonardo Baiocchi; Tianhao Zhou; Suthat Liangpunsakul; Lenci Ilaria; Martina Milana; Fanyin Meng; Lindsey Kennedy; Praveen Kusumanchi; Zhihong Yang; Ludovica Ceci; Shannon Glaser; Heather Francis; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-11       Impact factor: 4.052

10.  Cytoprotective Effects of Melatonin Against Amitriptyline-Induced Toxicity in Isolated Rat Hepatocytes.

Authors:  Shohreh Taziki; Mohammad Reza Sattari; Siavoush Dastmalchi; Mohammad Ali Eghbal
Journal:  Adv Pharm Bull       Date:  2015-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.